CYTR

[for3J1M]

thanks stocks2watch2. i think im FINALLY learning that. i didnt want to get stuck in one of those big drops after a run. this one can move fast and im not always around.ill add more if it drops. good luck to you

[Keichi]

looking to get in on the pullback. nice find

[stocks2watch2]

Hit 2.02  and pulled back a little.

[for3J1M]

wow,there is that pullback back i was afraid of. i bought a few back at 1.72

[stocks2watch2]

CytRx to Present at NYSSA 10th Annual Biotech & Specialty Pharmaceutical Conference
Business Wire - December 04, 2006 8:30 AM ET
   
CYTR Trade 1.88 +0.14
Real time quote.
 
CytRx Corporation (Nasdaq:CYTR) today announced that Matthew Natalizio, CytRx's Chief Financial Officer, is scheduled to present at The New York Society of Security Analysts (NYSSA) 10th Annual Biotech & Specialty Pharmaceutical Industry Conference on Tuesday, December 12, at 9:30 a.m. Eastern Time. The conference will be held on December 12, 2006, 8:30 a.m. to 5:10 p.m., and December 13, 2006, 8:30 a.m. to 4:30 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, New York City.

A live audio webcast and slide presentation will be available under "Events Calendar" in the "News & Events" section of the Company Web site at www.cytrx.com. An archived presentation will be available for 90 days starting approximately three hours after the initial presentation. To register for this conference or for more information, please visit www.nyssa.org.

NYSSA, established in 1937, is the premier independent forum for the exchange of information among investment decision-makers. A not-for-profit educational organization with over 9,500 members, NYSSA is committed to the promotion of best practices and the highest professional and ethical standards in the investment industry. NYSSA is the largest of the more than 134 societies worldwide that make up CFA Institute, which has more than 83,000 members.

[Keichi]

updated chart.
btw. the projected targets are not exact calculations. I'm just eyeballing the nearest # on the chart. Sorry, gotta be more disciplined.
cheers

[setravis]

"CYTR" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.   
All history on a stock pick in 1 thread is awesome.    

Thank You....and good luck with all your trades....make some $$$   

[Keichi]

Thanks Setravis, but can you change it to the correct symbol (CYTR)

[for3J1M]

I just noticed the pop on cytr  i missed the news this morning.

http://news.moneycentral.msn.com/ticker/article.aspx?Symbol=US:CYTR&Feed=BW&Date=20070109&ID=6326635

stocks2watch2, looks like you are heading towards that year to date high!

[stocks2watch2]

CytRx Corporation Subsidiary, RXi Pharmaceuticals, Licenses ``Nanotransporters'' and Other RNAi Discoveries from the University of Massachusetts Medical School
BusinessWire - January 11, 2007 8:30 AM ET
   

Related Quotes
Symbol   Last Chg
CYTR Trade 2.08 0.00
Real time quote.
 
CytRx Corporation (NASDAQ:CYTR) today announced that RXi Pharmaceuticals Corporation (RXi), a majority-owned subsidiary of CytRx, has entered into significant new agreements with the University of Massachusetts Medical School (UMMS) to license RNA interference (RNAi) intellectual property for all therapeutic applications. RNAi has been shown to effectively interfere with the expression of targeted disease-associated genes with great specificity and potency, and was co-discovered by 2006 Nobel Laureate Dr. Craig C. Mello, who is expected to become a scientific advisor of RXi pending institutional approval. The agreements include an exclusive therapeutic license with rights to sublicense for nanotransporters, which have been shown to deliver intact RNAi to a number of tissues in animal models. The licenses are contingent upon RXi's receipt of working capital funding in the coming months. Financial terms were not disclosed for competitive reasons.

Tod Woolf, Ph.D., CEO of RXi, stated, "The scientists that founded RXi realized long ago that delivery technology was the key to systemic administration of RNAi. The nanotransporters are the culmination of work carried out since 2003 by Dr. Tariq Rana of UMMS. This new technology, together with our existing RNAi-based intellectual property licenses acquired from CytRx, extraordinary scientific advisors and proven management team provides the foundation required to establish RXi as a pre-eminent company focused exclusively on the RNAi field. With Merck's acquisition of Sirna Therapeutics, RXi expects to compete primarily with industry leader Alnylam Pharmaceuticals as a company dedicated to developing and commercializing RNAi therapeutics. While other competitors have sought collaborators to obtain systemic delivery of RNAi, RXi now has its own potential enabling delivery technology," added Dr. Woolf.

"If RXi is able to offer a new method for treating a broad range of diseases, RNAi therapeutics could become as important as small molecules and antibody drugs," said Steven A. Kriegsman, President and CEO of CytRx.

Licensed Nanotransporter Technology

Tariq M. Rana, Ph.D., Professor and Founding Director of the Program in Chemical Biology at UMMS and developer of the nanotransporters, has reported activity with RNAi delivered with nanotransporters in mouse models at 1 milligram per kilogram - an exceptionally favorable dose. The nanotransporters are highly uniform in structure and are readily formulated by simply mixing with RNAi compounds. Results of this research were presented at the 2006 Keystone Conference.

The RXi licensed technology also includes compounds for the potential treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) that can be delivered locally to the central nervous system. The ability to control gene expression in the central nervous system has potentially far-reaching implications for the treatment of a number of neurodegenerative diseases. In addition, the technology includes methods of targeting point mutations with RNAi that may be useful in targeting mutations that cause certain cancers and genetic diseases.

[stocks2watch2]

I just noticed the pop on cytr  i missed the news this morning.

http://news.moneycentral.msn.com/ticker/article.aspx?Symbol=US:CYTR&Feed=BW&Date=20070109&ID=6326635

stocks2watch2, looks like you are heading towards that year to date high!

We did it,just broke out to new 52 week high of 2.33.

[pompano]

This stock is very hot, broke out of its downtrend and is definitely on its way to the mid 3s.  I  highly recommend this stock.

[stocks2watch2]

CytRx Corporation Subsidiary, RXi Pharmaceuticals, Obtains Option to License All Unrestricted Therapeutic RNAi Technologies Developed in the Next Three Years by the University of Massachusetts Medical School
BusinessWire - January 16, 2007 8:30 AM ET
   
 
CytRx Corporation (NASDAQ: CYTR) today announced that RXi Pharmaceuticals Corporation (RXi), a majority-owned subsidiary of CytRx, has entered into a master agreement with the University of Massachusetts Medical School (UMMS) that provides RXi option rights to license all unrestricted therapeutic RNAi technology developed at UMMS over the next three years, in return for cash payments and equity. RNAi has been shown to effectively interfere with the expression of targeted disease-associated genes with great specificity and potency.

Following disclosure by UMMS of new, unrestricted RNAi technologies, RXi will have the right, by making a specified cash payment to UMMS, to acquire an option to negotiate on an exclusive basis with UMMS to obtain a worldwide, exclusive license to the disclosed technology on commercially reasonable terms. The option rights are contingent upon RXi's receipt of working capital funding in the coming months. Financial terms were not disclosed for competitive reasons.

Since the co-discovery of RNAi by UMMS scientists in 1998, UMMS has played a leading role in developing potential RNAi therapeutics. RXi is already a licensee to many of these UMMS technologies.

"With this agreement, we gain access to new RNAi technologies developed at UMMS - the birthplace of RNAi. This agreement creates an excellent opportunity for RXi to license leading-edge breakthroughs in RNAi. Technology that we may acquire under this arrangement will further expand our already impressive portfolio of licenses to therapeutic RNAi intellectual property," said Tod Woolf, Ph.D., President and CEO of RXi.

[BigSully1]

CYTR ready for another leg up?

http://stockcharts.com/h-sc/ui?s=CYTR&p=D&b=5&g=0&id=p98393877330

[stocks2watch2]

This stock is very hot, broke out of its downtrend and is definitely on its way to the mid 3s.  I  highly recommend this stock.

You may be right On our way  new high today 2.61.